13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Sutent (clear cell renal)

    Acronym: 

    Sutent

    ACTRN/NCT /ethics: 

    Scientific title: 

    Improving Sunitinb Efficacy and tolerability in patients with metastatic clear cell carcinoma of the kidney by using a 14/7 day schedule and Toxicity-Adjusted Dosing (ISE TAD14-7)

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Tumour Stream Renal
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Kidney
    Trial Type Treatment
    Phase
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Renal
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Improving Sunitinb Efficacy and tolerability in patients with metastatic clear cell carcinoma of the kidney by using a 14/7 day schedule and Toxicity-Adjusted Dosing (ISE TAD14-7)

    Lay Summary

    Improving Sunitinb Efficacy and tolerability in patients with metastatic clear cell carcinoma of the kidney by using a 14/7 day schedule and Toxicity-Adjusted Dosing (ISE TAD14-7)

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Chris Karapetis Recruitment on Hold